NCT00479037 - Effect of Full Length Parathyroid Hormone, PTH(1-84) or Strontium Ranelate on Bone Markers in Postmenopausal Women With Primary Osteoporosis (FP-006-IM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

February 28, 2009

Study Completion Date

July 31, 2009

Conditions

Osteoporosis

Interventions

DRUG

Full Length Parathyroid Hormone, PTH(1-84)

Once daily subcutaneous injection in the abdomen by self administration

DRUG

Strontium Ranelate

The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water

Trial Locations (1)

4000

Nycomed, Roskilde